Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 27

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 27
---
. Net loss was $11,204,458 (of which $9,957,470 was due to derivative financial expenses) and $1,236,329 for the six months ended June 30, 2025, and June 30, 2024, respectively. During the six months ended June 30, 2025, and June 30, 2024, Kadimastem had negative cash flows from operations of $602,695 and $763,677, respectively. As of June 30, 2025, Kadimastem’s accumulated deficit was $87,734,255. Kadimastem has funded its operations to date through equity and debt financing and had cash on hand (including short -termbank deposits) of $298,932 as of June 30, 2025. Kadimastem’s net loss during the fiscal years ended December 31, 2024, December 31, 2023 was $7,178,333, and $3,254,423, respectively. During the fiscal years ended December 31, 2024, and December 31, 2023, Kadimastem had negative cash flows from operations in the amount of $705,483, and $2,995,813, respectively. As of December 31, 2024, Kadimastem’s accumulated deficit was $76,529,697, compared to an accumulated deficit of $69,345,362 as of December 31, 2023. Kadimastem monitors its cash flow projections on a current basis and take active measures to obtain the funding it requires to continue Kadimastem’s operations. However, these cash flow projections are subject to various uncertainties concerning their fulfilment. If Kadimastem is not successful in generating sufficient cash flow or completing additional financing, including debt refinancing which shall release restricted cash, then Kadimastem will need to execute a new cost reduction plan in addition to previous cost reduction plans that were executed so far. Kadimastem’s transition to profitable operations is dependent on generating a level of revenue adequate to support Kadimastem’s cost structure. Kadimastem expects to fund operations using cash on hand, through operational cash flows and raising additional proceeds. There are no assurances, however, that Kadimastem will be able to generate the revenue necessary to support Kadimastem’s cost structure or that Kadimastem will be successful in obtaining the level of financing necessary